March 12, 2019
UCB Japan and Otsuka Pharmaceutical said on March 11 that they will not extend the existing agreement to codevelop and copromote UCB’s antiepileptic agent E Keppra (levetiracetam) in Japan, when it winds up in September 2020. Under the agreement struck...read more